gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Apoptotic peptidase activating factor 1

Apaf-1, Apoptotic Protease-Activating Factor 1, Axl, Ark
This gene encodes a cytoplasmic protein that initiates apoptosis. This protein contains several copies of the WD-40 domain, a caspase recruitment domain (CARD), and an ATPase domain (NB-ARC). Upon binding cytochrome c and dATP, this protein forms an oligomeric apoptosome. The apoptosome binds and cleaves caspase 9 preproprotein, releasing its mature, activated form. Activated caspase 9 stimulates the subsequent caspase cascade that commits the cell to apoptosis. Alternative splicing results in several transcript variants encoding different isoforms. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: Gas6, PrP, CAN, TIF, V1a
Papers using Apaf-1 antibodies
Using process diagrams for the graphical representation of biological networks
Levchenko Andre, In PLoS Biology, 2004
... Antibodies were obtained as follows: cPARP, cleaved C3, XIAP, Bid, and Apaf-1 (BD Biosciences); C6, C8, and PARP ...
Growing roles for the mTOR pathway
Wang Aiyuan et al., In Molecular Cancer, 2004
... EGFR (immunoprecipitation), phosphotyrosine (PY99), p53 and PCNA and polyclonal antibodies to EGFR, ERBB4, MET and AXL were from Santa Cruz Biotechnology (Santa Cruz, CA, USA) ...
Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis
Auberger Patrick et al., In Oncotarget, 2003
... Anti-HSP90, anti-HSP60, anti-tubulin and anti-AXL antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) ...
APAF1 is a key transcriptional target for p53 in the regulation of neuronal cell death
Slack Ruth S. et al., In The Journal of Cell Biology, 2000
... Apaf1-deficient transgenic mice have been described ...
Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1
Dulak Jozef et al., In Genetic Vaccines and Therapy, 1997
... Proliferating cell nuclear antigen (PCNA) recognizing primary antibodies (clone PC10) and Animal Research Kit (ARK) Peroxidase were procured from DAKO (Gdynia, Poland) ...
Papers on Apaf-1
Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy.
Baselga et al., Kettering, United Kingdom. In Clin Cancer Res, Feb 2016
UNASSIGNED: AXL is a tyrosine kinase membrane receptor that signals via the phosphatidylinositol-3-kinases (PI3K), mitogen-activated protein kinases (MAPK) and protein kinase C (PKC), among other pathways.
The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl.
Lipkowitz et al., Bethesda, United States. In Breast Cancer Res Treat, Feb 2016
Expression levels of vimentin and Axl were then explored in 177 TNBC samples from a publically available cDNA microarray dataset and by immunohistochemistry (IHC) in tumor tissue samples obtained from 53 African-American women with TNBC.
Hepatic miR-126 is a Potential Plasma Biomarker for Detection of Hepatitis B Virus Infected Hepatocellular Carcinoma.
Banerjee et al., Calcutta, India. In Int J Cancer, Feb 2016
To understand the physiological role of these two miRNAs in hepato-carcinogenesis, target genes related to cancer pathways (APAF1, APC2, CDKN2A, IRS1, CRKL, LIFR, EGR2) were verified.
Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.
Jarzab et al., Gliwice, Poland. In Expert Rev Clin Pharmacol, Jan 2016
Cabozantinib (XL-184) is a potent inhibitor of MET, VEGFR 2/KDR, RET and other receptor tyrosine kinases, such as KIT, AXL and FLT3.
The TAM receptor Mertk protects against neuroinvasive viral infection by maintaining blood-brain barrier integrity.
Diamond et al., Saint Louis, United States. In Nat Med, Dec 2015
The TAM receptors Tyro3, Axl and Mertk are receptor tyrosine kinases that dampen host innate immune responses following engagement with their ligands Gas6 and Protein S, which recognize phosphatidylserine on apoptotic cells.
Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: An Update.
Ahsan, Ann Arbor, United States. In Adv Exp Med Biol, Dec 2015
Further, the rationale to utilize the combination therapies to simultaneously target EGFR and other major oncogene addictive pathway such as ERBB2 and AXL kinase is outlined.
Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial.
Joshua et al., Israel. In J Transl Med, Dec 2015
Plasma concentrations of VEGFA, FLT3L, c-MET, AXL, Gas6A, bone-specific alkaline phosphatase, interleukin-8 and the hypoxia markers CA9 and clusterin significantly increased during treatment with cabozantinib irrespective of response.
Strong Expression of Hypoxia-Inducible Factor-1α (HIF-1α) Is Associated with Axl Expression and Features of Aggressive Tumors in African Breast Cancer.
Akslen et al., Bergen, Norway. In Plos One, Dec 2015
PURPOSE: Inhibition of hypoxia-inducible factor (HIF) and Axl receptor tyrosine kinase is being evaluated for targeted therapy in solid tumors.
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
METEOR Investigators et al., Villejuif, France. In N Engl J Med, Dec 2015
BACKGROUND: Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL, each of which has been implicated in the pathobiology of metastatic renal-cell carcinoma or in the development of resistance to antiangiogenic drugs.
Mechanisms of resistance to EGFR tyrosine kinase inhibitors.
Fu et al., Guangzhou, China. In Acta Pharm Sin B, Sep 2015
Resistance to EGFR-TKIs is inevitable due to various mechanisms, such as the secondary mutation (T790M), activation of alternative pathways (c-Met, HGF, AXL), aberrance of the downstream pathways (K-RAS mutations, loss of PTEN), impairment of the EGFR-TKIs-mediated apoptosis pathway (BCL2-like 11/BIM deletion polymorphism), histologic transformation, ATP binding cassette (ABC) transporter effusion, etc.
AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.
Baselga et al., New York City, United States. In Cancer Cell, May 2015
This persistent mTOR activation is mediated by the tyrosine kinase receptor AXL.
Cell Death in C. elegans Development.
Shaham et al., New York City, United States. In Curr Top Dev Biol, 2014
A core pathway consisting of the conserved proteins EGL-1/BH3-only, CED-9/BCL2, CED-4/APAF1, and CED-3/caspase promotes most cell death in the nematode, and a conserved set of proteins ensures the engulfment and degradation of dying cells.
Role of DNA methylation in renal cell carcinoma.
Verma et al., United States. In J Hematol Oncol, 2014
In particular, members of the Wnt and TGF-beta pathways, pro-apoptotic genes such as APAF-1 and negative cell-cycle regulators such as KILLIN have been shown to be epigenetically silenced in numerous studies in ccRCC.
The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer.
Earp et al., In Nat Rev Cancer, 2014
The TYRO3, AXL (also known as UFO) and MERTK (TAM) family of receptor tyrosine kinases (RTKs) are aberrantly expressed in multiple haematological and epithelial malignancies.
TAM receptor signaling in immune homeostasis.
Ghosh et al., In Annu Rev Immunol, 2014
The TAM receptor tyrosine kinases (RTKs)-TYRO3, AXL, and MERTK-together with their cognate agonists GAS6 and PROS1 play an essential role in the resolution of inflammation.
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
Bivona et al., Cleveland, United States. In Nat Genet, 2012
increased activation of AXL and evidence for epithelial-to-mesenchymal transition in multiple in vitro and in vivo EGFR-mutant lung cancer models with acquired resistance to erlotinib in the absence of the EGFR p.Thr790Met alteration or MET activation
AXL and acquired resistance to EGFR inhibitors.
Ashworth et al., In Nat Genet, 2012
mechanism of acquired resistance to EGFR inhibitors through the induction of AXL and its ligand GAS6 in NSCLC
Targeted Casp8AP2 methylation increases drug resistance in mesenchymal stem cells and cancer cells.
Leu et al., Taiwan. In Biochem Biophys Res Commun, 2012
These data demonstrate that methylation within the Casp8AP2 promoter correlates with the development of drug resistance and might serve as a biomarker and treatment target for drug resistance in cancer cells.
Immune modulation of vascular resident cells by Axl orchestrates carotid intima-media thickening.
Korshunov et al., Rochester, United States. In Am J Pathol, 2012
Axl contributes to carotid remodeling not only by inhibition of apoptosis but also via regulation of immune heterogeneity of vascular cells, cytokine/chemokine expression, and extracellular matrix remodeling.
Cross-phosphorylation, signaling and proliferative functions of the Tyro3 and Axl receptors in Rat2 cells.
Prieto et al., Bloomington, United States. In Plos One, 2011
Overexpression of Tyro3 in the Rat2 cell line that expresses Axl, but not Mer or Tyro3, resulted in a 5 fold increase in cell proliferation.
share on facebooktweetadd +1mail to friends